Tenofovir: new indication. In chronic hepatitis B: beware bone toxicity.
Tenofovir is more effective than adefovir in reducing viraemia in the short term, but with no histological or serological evidence of improvement. It is also associated with a small increase in gastrointestinal disturbances and exacerbation of hepatitis. Its renal and bone risks also need to be closely monitored.
D000225:Adenine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use / Q000633:toxicity; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D001847:Bone Diseases / Q000139:chemically induced*; D001842:Bone and Bones / Q000187:drug effects*; D004311:Double-Blind Method; D017277:Drug Approval; D005060:Europe; D050723:Fractures, Bone / Q000139:chemically induced*; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D063065:Organophosphonates / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D016032:Randomized Controlled Trials as Topic; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D000068698:Tenofovir; D014766:Viremia / Q000188:drug therapy* / Q000821:virology; D014779:Virus Replication / Q000187:drug effects*
D000998:Antiviral Agents; D063065:Organophosphonates; D018894:Reverse Transcriptase Inhibitors; D000068698:Tenofovir; D000225:Adenine